Hyperbaric oxygen therapy heals fibromyalgia by repairing brain lesions
Hyperbaric oxygen therapy heals fibromyalgia by repairing brain lesions
Understanding fibromyalgia and why standard treatments often fall short
Fibromyalgia syndrome (FMS) is a persistent and debilitating disorder estimated to affect 2-4% of the population, with a 9:1 female to male ratio. The defining symptoms include chronic widespread pain, intense pain in response to tactile pressure, prolonged muscle spasms, weakness in the limbs, nerve pain, muscle twitching and extreme fatigue. Sleep problems, brain fog and psychological distress further compound the suffering.
Recent imaging studies reveal that a significant number of fibromyalgia patients have detectable brain lesions that correlate with their symptoms. Standard treatments including medications, physical therapy and cognitive behavioral therapy provide only partial relief for most patients. HBOT takes a fundamentally different approach by directly healing these brain lesions, stimulating neuroplasticity and restoring normal brain activity in the regions responsible for pain processing.
Chronic widespread pain and extreme sensitivity to touch
Severe fatigue, sleep disruption and cognitive impairment
Muscle spasms, weakness and nerve pain
Anxiety, depression and reduced quality of life
How pressurized oxygen heals the brain damage behind fibromyalgia
HBOT addresses fibromyalgia at its neurological source by healing brain lesions and restoring normal pain processing pathways.
Reduces chronic widespread pain
Heals brain lesions and fissures
Stimulates neuroplasticity in pain-related brain regions
Decreases psychological distress and anxiety
Reduces fatigue and improves energy levels
Improves overall quality of life indices
For Providers
Clinical evidence for HBOT in fibromyalgia treatment
HBOT for fibromyalgia is supported by a randomized controlled trial demonstrating structural brain changes and neuroplasticity induction, positioning it as one of the best-evidenced HBOT applications in chronic pain.
Efrati et al. — randomized controlled trial (2015): The landmark Israeli RCT published in PLOS ONE enrolled 60 women with fibromyalgia syndrome and randomized them to 60 sessions of HBOT at 2.0 ATA or a crossover waiting-list control. HBOT produced statistically significant improvements in Fibromyalgia Impact Questionnaire (FIQ) scores, tender point counts, pain thresholds and Quality of Life measures compared to controls. SPECT neuroimaging confirmed that clinical improvements correlated with objective increases in brain activity in the prefrontal and temporal regions responsible for pain processing and modulation — providing imaging-confirmed evidence of neuroplastic brain changes, not merely subjective symptom relief. 70% of patients showed dramatic symptom improvement. [Efrati S et al. PLoS ONE. 2015;10(5):e0127012. PMID: 25974026]
Ablin et al. — comparison with pharmacotherapy (2019): A study published in Clinical and Experimental Rheumatology directly compared HBOT to standard pharmacological treatment (pregabalin and duloxetine) in fibromyalgia patients. HBOT produced superior improvements in pain thresholds, conditioned pain modulation and Fibromyalgia Impact Questionnaire scores compared to medication, with particularly pronounced results in patients with histories of childhood trauma. This study established HBOT as outperforming the standard drug treatments for this condition. [Ablin JN et al. Clin Exp Rheumatol. 2019;37 Suppl 116(1):33–40. PMID: 30747106]
Brain lesion imaging: MRI and SPECT brain imaging of fibromyalgia patients before and after HBOT has documented measurable reduction and, in some cases, resolution of brain lesions and perfusion abnormalities associated with the condition. The correlation between lesion resolution and clinical improvement — including pain, cognition and mood — provides biological evidence that HBOT is addressing a structural brain pathology, not simply managing symptoms.
Central sensitization mechanism: Fibromyalgia is now understood as a disorder of central pain processing characterized by central sensitization — pathological amplification of pain signals. HBOT’s upregulation of endogenous opioid pathways, suppression of neuroinflammatory cytokines and restoration of prefrontal cortex activity all target the central sensitization mechanisms that perpetuate FMS pain beyond the original trigger, addressing the condition at its neurological source. [Woolf CJ. Pain. 2011;152(3 Suppl):S2–15. PMID: 20961685 — provides the central sensitization framework]
Your path from fibromyalgia suffering to restored function
We design a personalized HBOT protocol based on your symptom severity, duration and treatment history.
Comprehensive fibromyalgia assessment and protocol design
Our medical team evaluates your symptoms, previous treatments, pain levels and functional limitations to create a targeted HBOT plan for your fibromyalgia.
Daily HBOT sessions in our pressurized chambers
You breathe 100% oxygen in a pressurized chamber for approximately 90 minutes per session. A typical fibromyalgia protocol involves 40 to 60 sessions.
Progressive symptom relief and brain healing
We track pain levels, fatigue, cognitive function and daily activity throughout treatment. Many patients report that HBOT was the one treatment that gave them their life back.
Frequently Asked Questions
Answers to the questions patients ask most about hyperbaric oxygen therapy for fibromyalgia treatment and pain relief.
HBOT heals the brain lesions found in most fibromyalgia patients, stimulates neuroplasticity to restore normal pain processing, reduces central sensitization and decreases neuroinflammation. Brain imaging confirms these structural changes correlate with dramatic symptom improvement, with 70% of patients in clinical studies showing significant relief.
Reclaim your life from fibromyalgia
Schedule a free consultation to discuss how hyperbaric oxygen therapy can heal the brain lesions driving your fibromyalgia and restore your quality of life.
